Virtual Screening of Leishmanial Pyridoxal Kinase Enzyme Inhibitors by Repurposed Anti-Trypanosomal Libraries Reveals Two Core Scaffolds

13 October 2020, Version 1
This content is a preprint and has not undergone peer review at the time of posting.


Leishmania is an intracellular protozoal infection, and it is classified as a neglected disease by the World Health Organization (WHO). Annually more than 2 million newly diagnosed cases were treated with highly toxic drugs. Leishmanial pyridoxal kinase enzyme (LPDxK) is an essential and druggable target. DNDI1103666 is the most promising lead as a potential inhibitor for LPDxK


Neglected diseases
virtual screening
Leishmanial pyridoxal kinase inhibitors

Supplementary weblinks


Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.